+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

MIP-3β/CCL19 is associated with the intrathecal invasion of mononuclear cells in neuroinflammatory and non-neuroinflammatory CNS diseases in dogs

MIP-3β/CCL19 is associated with the intrathecal invasion of mononuclear cells in neuroinflammatory and non-neuroinflammatory CNS diseases in dogs

Bmc Veterinary Research 10: 157

Chemokines such as MIP-3β/CCL19 are important factors in the mechanism of cell migration and pathogenesis of central nervous system (CNS) inflammatory reactions. The hypothesis of this study is that CCL19, also known as MIP-3β, is involved in the pathogenesis of inflammatory and non-inflammatory CNS diseases of dogs. Experiments were performed on cerebrospinal fluid (CSF) and serum samples of dogs affected with steroid responsive meningitis-arteritis (SRMA) during the acute phase as well as during treatment. Dogs with SRMA were compared to dogs with presumed meningoencephalomyelitis of unknown origin (MUO), and both groups sub-categorized into dogs receiving no therapy and with patients receiving prednisolone therapy. Idiopathic epilepsy (IE), a group with normal CSF cell count, was used as a control. Additionally, dogs with intervertebral disc disease (IVDD) of varying severity were analyzed. Chemokine concentrations were determined by enzyme linked immunosorbent assay. Migration assays were performed on seven selected CSF samples using a disposable 96-well chemotaxis chamber. CCL19 was detectable in CSF samples of all dogs. Dogs with untreated SRMA and MUO displayed pronounced CCL19 elevations compared to the control group and patients receiving glucocorticosteroid treatment. CSF cell counts of untreated SRMA and MUO patients were significantly positively correlated with the CCL19 CSF concentration. IVDD patients also had elevated CCL19 concentration compared to controls, but values were considerably lower than in inflammatory CNS diseases. Selected CSF samples displayed chemotactic activity for mononuclear cells in the migration assay. CCL19 CSF concentrations were markedly elevated in patients affected with the neuroinflammatory diseases SRMA and MUO and showed a strong correlation with the CSF cell count. This chemokine may play an important role in the pathogenesis of SRMA and MUO. The elevation of CSF CCL19 in IVDD suggests that it may also be involved in the secondary wave of spinal cord injuries.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 054207885

Download citation: RISBibTeXText

PMID: 25016392

DOI: 10.1186/1746-6148-10-157

Related references

Chemokine mRNA expressing mononuclear cells in blood and CSF in neuroinflammatory diseases. Journal of the Neurological Sciences 150(SUPPL ): S116-S117, 1997

Neuroinflammatory disease. IBC meeting on neuroinflammatory disease: research and treatment strategies. London, UK, 17 and 18 September 1996. Molecular Medicine Today 3(1): 12-13, 1997

Dendritic cells in autoimmune diseases and neuroinflammatory disorders. Frontiers in Bioscience 12: 4315-4335, 2007

Immunophenotypic characterization of CSF B cells in virus-associated neuroinflammatory diseases. Plos Pathogens 14(4): E1007042, 2018

The Trojan horse - neuroinflammatory impact of T cells in neurodegenerative diseases. Molecular Neurodegeneration 12(1): 78, 2018

Involvement of benzodiazepine receptors in neuroinflammatory and neurodegenerative diseases: evidence from activated microglial cells in vitro. Neurobiology of Disease 14(3): 417-424, 2003

Autophagy in neuroinflammatory diseases. Autoimmunity Reviews 16(8): 856-874, 2017

The IL-1β phenomena in neuroinflammatory diseases. Journal of Neural Transmission 125(5): 781-795, 2017

Endocannabinoid signaling and neuroinflammatory diseases. Current Pharmaceutical Design 14(23): 2252-2253, 2008

Inflammasomes in neuroinflammatory and neurodegenerative diseases. Embo Molecular Medicine 2019, 2019

Monoclonal antibodies in neuroinflammatory diseases. Expert Opinion on Biological Therapy 13(6): 831-846, 2013

Therapeutic approaches to the treatment of neuroinflammatory diseases. Current Pharmaceutical Design 4(4): 335-348, 1999

Role of prostaglandins in neuroinflammatory and neurodegenerative diseases. Mediators of Inflammation 2012: 946813, 2012

Method of treating neuroinflammatory degenerative diseases. Official Gazette of the United States Patent & Trademark Office Patents 1209(2): 1419-1420, April 14, 1998

Neuroinflammatory paradigms in lysosomal storage diseases. Frontiers in Neuroscience 9: 417, 2015